GlassScriptPhysician profile
Steven J Feldman
NPI 1881679165
$5,065.28
in general payments reported to CMS, 2019-2025
37 companies · $867 in 2025
The $867 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $882 · 2020: $150 · 2021: $313 · 2022: $707 · 2023: $969 · 2024: $1,176 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,012.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $510.70 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $480.81 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $461.88 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $430.91 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $389.42 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $354.02 | 2021-2025 | |
| Glaxosmithkline, LLC. | $269.54 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $231.34 | 2019-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $184.94 | 2022-2024 | |
| Abbott Laboratories | $177.17 | 2019-2025 | Freestyle Libre 2, Freestyle Libre 3, Thoratec Heartmate 3 Lvas Implant Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.62 | 2019-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.18 | 2021-2025 | Jardiance, Spiriva Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $149.63 | 2022-2024 | |
| Noven Pharmaceuticals, INC. | $124.74 | 2024 | Xelstrym |
| Amarin Pharma, INC. | $124.24 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $92.56 | 2022-2023 | Quviviq |
| Bausch Health US, LLC | $84.01 | 2022 | |
| Radius Health, INC. | $81.86 | 2019-2020 | |
| Exact Sciences Corporation | $71.65 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sanofi Pasteur INC. | $71.39 | 2020-2023 | |
| Axsome Therapeutics, INC. | $70.11 | 2024-2025 | Auvelity |
| Amneal Pharmaceuticals LLC | $60.42 | 2019-2023 | Unithroid |
| Esperion Therapeutics, INC. | $37.61 | 2023-2025 | Nexletol |
| Daiichi Sankyo INC. | $32.57 | 2021-2024 | Injectafer |
| Janssen Pharmaceuticals, INC | $32.11 | 2019 | |
| Tactile Systems Technology INC | $19.93 | 2024 | Entre Plus, Flexitouch Plus |
| Dexcom, INC. | $19.86 | 2023 | Dexcom G6 Transmitter |
| Si-Bone, INC. | $18.87 | 2023 | |
| Astellas Pharma US INC | $18.00 | 2019 | |
| Seqirus USA INC | $17.90 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $16.87 | 2024 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $15.80 | 2024 | Eliquis |
| Shield Therapeutics INC | $15.22 | 2024 | |
| Ucb, INC. | $14.52 | 2024 | Nayzilam |
| Genentech USA, INC. | $13.88 | 2020 | |
| Lucid Diagnostics INC. | $13.19 | 2023 | |
| Vivaquant INC, Dba Rhythm Express | $10.81 | 2024 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.